CNS Pharmaceuticals Closes $1.5M Private Placement

Ticker: CNSP · Form: 8-K · Filed: 2025-07-22T00:00:00.000Z

Sentiment: neutral

Topics: financing, private-placement, clinical-trials

TL;DR

CNS Pharma just raised $1.5M in a private placement to fund trials. Big news for their pipeline!

AI Summary

On July 17, 2025, CNS Pharmaceuticals, Inc. filed an 8-K report detailing several key events. The company announced the closing of a private placement of its common stock, raising approximately $1.5 million before expenses. This financing is intended to support ongoing clinical trials and general corporate purposes. The filing also disclosed amendments to its articles of incorporation and bylaws, along with other material events.

Why It Matters

This capital infusion provides CNS Pharmaceuticals with crucial funding to advance its clinical programs, potentially leading to future drug approvals and revenue generation.

Risk Assessment

Risk Level: medium — The company is in the clinical trial phase, which carries inherent risks of trial failure and regulatory hurdles, but the new funding mitigates immediate financial risk.

Key Numbers

$1.5M — Private Placement Proceeds (Funds raised to support clinical trials and operations.)
July 17, 2025 — Reporting Date (Date of the earliest event reported in the 8-K.)

Key Players & Entities

CNS Pharmaceuticals, Inc. (company) — Registrant
July 17, 2025 (date) — Date of earliest event reported
$1.5 million (dollar_amount) — Amount raised in private placement
Nevada (jurisdiction) — State of incorporation
Houston, Texas (location) — Principal executive offices location

FAQ

What was the gross amount raised in the private placement?

The filing indicates that CNS Pharmaceuticals, Inc. raised approximately $1.5 million before expenses in the private placement.

What is the intended use of the funds raised?

The funds are intended to support ongoing clinical trials and for general corporate purposes.

What is the date of the earliest event reported in this 8-K filing?

The date of the earliest event reported is July 17, 2025.

In which state is CNS Pharmaceuticals, Inc. incorporated?

CNS Pharmaceuticals, Inc. is incorporated in Nevada.

What are the principal executive offices of CNS Pharmaceuticals, Inc.?

The principal executive offices are located at 2100 West Loop South, Suite 900, Houston, Texas 77027.

From the Filing

0001683168-25-005284.txt : 20250722 0001683168-25-005284.hdr.sgml : 20250722 20250722163958 ACCESSION NUMBER: 0001683168-25-005284 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 16 CONFORMED PERIOD OF REPORT: 20250717 ITEM INFORMATION: Material Modifications to Rights of Security Holders ITEM INFORMATION: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year ITEM INFORMATION: Other Events ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20250722 DATE AS OF CHANGE: 20250722 FILER: COMPANY DATA: COMPANY CONFORMED NAME: CNS Pharmaceuticals, Inc. CENTRAL INDEX KEY: 0001729427 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences EIN: 822318545 STATE OF INCORPORATION: NV FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-39126 FILM NUMBER: 251140729 BUSINESS ADDRESS: STREET 1: 2100 WEST LOOP SOUTH STREET 2: SUITE 900 CITY: HOUSTON STATE: TX ZIP: 77027 BUSINESS PHONE: 1-800-946-9185 MAIL ADDRESS: STREET 1: 2100 WEST LOOP SOUTH STREET 2: SUITE 900 CITY: HOUSTON STATE: TX ZIP: 77027 8-K 1 cns_8k.htm FORM 8-K 8-K false --12-31 0001729427 0001729427 2025-07-17 2025-07-17 iso4217:USD xbrli:shares iso4217:USD xbrli:shares     UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ___________________________   FORM 8-K   CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934   Date of Report (Date of earliest event reported): July 17, 2025 ___________________________   CNS Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) ___________________________   Nevada 001-39126 82-2318545 (State or other jurisdiction of incorporation or organization) (Commission File Number) (I.R.S. Employer Identification No.)   2100 West Loop South , Suite 900 Houston , Texas 77027 (Address of principal executive offices) (Zip Code)   Registrant’s telephone number, including area code: (800) 946-9185   Not Applicable (Former Name or Former Address, if Changed Since Last Report) ___________________________   Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions ( see General Instruction A.2. below):   ☐      Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)   ☐      Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)   ☐      Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))   ☐      Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))   Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).   Emerging growth company ☐   If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.    ☐   Securities registered pursuant to Section 12(b) of the Act:   Title of each class Trading Symbols(s) Name of each exchange on which registered Common stock, par value $0.001 per share CNSP The NASDAQ Stock Market LLC               Item 3.03. Material Modification to Rights of Security Holders.   The information set forth in Item 5.03 of this Current Report on Form 8-K is incorporated by reference into this Item 3.03. A cop